News
AVTX
20.25
-6.12%
-1.32
Avalo Therapeutics Price Target Raised to $60.00/Share From $48.00 by Piper Sandler
Dow Jones · 12h ago
Avalo Therapeutics Is Maintained at Overweight by Piper Sandler
Dow Jones · 12h ago
Piper Sandler Maintains Overweight on Avalo Therapeutics, Raises Price Target to $60
Benzinga · 12h ago
Weekly Report: what happened at AVTX last week (0504-0508)?
Weekly Report · 15h ago
U.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla
Reuters · 16h ago
AVALO THERAPEUTICS INC <AVTX.O>: PIPER SANDLER RAISES TARGET PRICE TO $60 FROM $48
Reuters · 20h ago
Avalo CFO Christopher Sullivan disposes of common shares worth $1.03 million
PUBT · 4d ago
Avalo CMO Mittie Doyle disposes 108,234 shares worth $2.28 million
PUBT · 4d ago
Avalo Chief Legal Officer Paul Varki disposes of common shares worth $1.49 million
PUBT · 4d ago
Avalo Therapeutics director Mitchell Chan sells 3,167 shares for $72,478.96
PUBT · 4d ago
Avalo Therapeutics: Abdakibart Delivers Breakout Phase 2 HS Data
Seeking Alpha · 4d ago
Avalo Therapeutics Announces Major Equity and Warrant Offering
TipRanks · 4d ago
Avalo Therapeutics 19.73M share Spot Secondary priced at $17.75
TipRanks · 4d ago
Avalo Therapeutics price target raised to $58 from $40 at BTIG
TipRanks · 4d ago
Avalo Therapeutics Stock Soars After Positive LOTUS Trial Results
Benzinga · 5d ago
Guggenheim Keeps Their Buy Rating on Avalo Therapeutics (AVTX)
TipRanks · 5d ago
BUZZ-U.S. STOCKS ON THE MOVE-Instacart, New York Times, Novavax
Reuters · 5d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 5d ago
Morning News Wrap-Up, 5/6/26: Today’s Biggest Stock Market Stories!
TipRanks · 5d ago
BUZZ-U.S. STOCKS ON THE MOVE-DaVita, Knight-Swift, Madrigal Pharma
Reuters · 5d ago
More
Webull provides a variety of real-time AVTX stock news. You can receive the latest news about Avalo Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About AVTX
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.